Clinical Trial Update: Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the safety of reinfusing axicabtagene ciloleucel (Axi-Cel-2) in patients with relapsed/refractory second-line high-risk non-Ho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Axicabtagene ciloleucel (axicabtagene ciloleucel)

Snippet

Sponsor: Stanford University | Conditions: Non-Hodgkin Lymphoma, Large B-cell Lymphoma | Phase 1 | Status: RECRUITING